Commercial DURAClone panels for extending the repertoire of multicolour immunophenotypic panels in an academic flow cytometry laboratory in South Africa

African Journal of Laboratory Medicine

 
 
Field Value
 
Title Commercial DURAClone panels for extending the repertoire of multicolour immunophenotypic panels in an academic flow cytometry laboratory in South Africa
 
Creator Swart, Leanne Pretorius, Melanie Lawrie, Denise Glencross, Deborah K.
 
Subject Health; laboratory science flow cytometry; multicolour; immunophenotyping; lymphoma; leukaemia; plasma cell dyscrasia; acute lymphoblastic leukaemia; B-cell lymphoproliferative disorder; lyophilised reagent; fixed panels
Description Background: Commercial multicolour fixed immunophenotyping panels can improve flow cytometric diagnostic immunophenotyping repertoire.Objective: This study validated the commercially available, standardised Beckman Coulter lyophilised DURAClone RE panels to discriminate specific haematolymphoid subtypes.Methods: We compared the diagnostic capability of the DURAClone acute leukaemia B (ALB), chronic leukaemia B (CLB), and plasma cells (PC) panels to the predicate second-line panels in Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa, from April to August 2020. Clinical diagnostic concordance between the in-house second-line immunophenotyping (the predicate method) and DURAClone was established. The ALB panels tested for precursor B-cell acute lymphoblastic leukaemia (n = 11) or normal bone marrow haematogones (n = 9); CLB panels established haematolymphoid subtypes of mature B-cell lymphoproliferative disorders (B-LPD) (n = 20), while PC panels detected plasma cell dyscrasias (PCD) (n = 17). Flow cytometer setup and data interpretation to discriminate normal and aberrant immunophenotypes were per manufacturer’s instructions.Results: There was 100% clinical diagnostic concordance between the predicate and the test panels for second-line diagnostic investigation of B-ALL (with additional CD56), mature B-LPD (with additional discernment of CD81, ROR-1, CD79b and CD43) and PCD.Conclusion: The DURAClone CLB exceeded the predicate second-line performance, offering extended second-line diagnostic discernment of mature B-LPD subtypes and discernment of CD5+ B-LPD from other non-CD5+ (or CD5–) B-LPD; likewise, the PC panels enabled discovery of PCD. While ALB testing offered no additional diagnostic advantage over existing predicate investigation, CD58 did offer additional information to discern haematogones from B-ALL. 
 
Publisher AOSIS
 
Contributor none
Date 2022-11-29
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — prospective observational cohort study
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/ajlm.v11i1.1720
 
Source African Journal of Laboratory Medicine; Vol 11, No 1 (2022); 9 pages 2225-2010 2225-2002
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://ajlmonline.org/index.php/ajlm/article/view/1720/2498 https://ajlmonline.org/index.php/ajlm/article/view/1720/2499 https://ajlmonline.org/index.php/ajlm/article/view/1720/2500 https://ajlmonline.org/index.php/ajlm/article/view/1720/2501
 
Coverage South Africa 2020 sample type
Rights Copyright (c) 2022 Leanne Swart, Melanie Pretorius, Denise Lawrie, Deborah K. Glencross https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT